Bayer will offer Veracyte's Afirma Xpression Atlas to identify underlying drivers in tumors of late-stage or metastatic thyroid cancer patients resistant to radioactive iodine therapy.
The partners are starting by testing patients with colorectal and thyroid cancers using the 648-gene Tempus xT assay, but could expand to other areas in the future.
In PNAS this week: genetic variants linked to a pediatric periodic fever syndrome, TERT promoter mutations influencing BRAF and MEK inhibitor response, and more.
An analysis of pediatric cancer survivors suggests subsequent neoplasm risk can increase after certain genotoxic treatments in those with DNA repair gene changes.
In PNAS this week: 10-SNP polygenic risk score for papillary thyroid cancer performs as well as a larger one, loss-of-function mutation affecting voltage-gated sodium channel, and more.
The company anticipates launching an in vitro diagnostic version of the 10-gene ThyroidPrint assay in South America and Europe after receiving regulatory clearance by Q2 2021.
